Pipeline

January 14, 2019
Company Drug/Device Medical Condition Status
Oppilan Pharma Ltd. OPL-002 inflammatory bowel disease (IBD) Phase I trial initiated enrolling 72 subjects
Pliant Therapeutics, Inc. PLN-74809 idiopathic pulmonary fibrosis Phase I trial initiated enrolling 90 healthy subjects
Deciphera Pharmaceuticals, Inc. rebastinib in combination with carboplatin advanced or metastatic solid tumors Phase Ib/II trial initiated enrolling 117 subjects (18 subjects in Part 1 and 99 subjects in Part 2)
Protagonist Therapeutics, Inc. PTG-300 beta thalassemia Phase II trial initiated enrolling 84 adolescent and adult subjects
Galapagos NV GLPG1690 systemic sclerosis (SSc, or scleroderma) Phase IIa trial initiated enrolling 30 subjects with diffuse cutaneous SSc
Urovant Sciences vibegron abdominal pain due to irritable bowel syndrome (IBS) Phase IIa trial initiated enrolling 200 female subjects
Seres Therapeutics, Inc. SER-287 active mild-to-moderate ulcerative colitis Phase IIb trial initiated enrolling 200 subjects
Pfizer, Inc. PF-06651600 moderate to severe alopecia areata Phase IIb/III trial initiated enrolling 660 subjects
NeuroBo Pharmaceuticals, Inc. NB-01 diabetic neuropathic pain Phase III trial initiated enrolling 717 adult subjects at 80 sites in the U.S.
Tivic Health Systems, Inc. ClearUP sinus pain due to allergic rhinitis (hay fever) 510(k) clearance granted by the FDA
StemCyte Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) spinal cord injury IND approval granted by the FDA
MicroVention, Inc. WEB Aneurysm Embolization System intracranial wide neck bifurcation aneurysms PMA approval granted by the FDA
Rainier Therapeutics, Inc. vofatamab advanced or metastatic urothelial cell carcinoma (bladder cancer) that is positive for FGFR3 mutation and/or fusion Fast Track Designation granted by the FDA
Grifols Erytra Eflexis blood grouping Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here